News

September 8, 2017September 8, 2017

LUM Imaging System to Detect Residual Cancer During Surgery to Start Advanced Clinical Trial

News

A possibly pivotal clinical trial using an imaging technology – the LUM Imaging System by Lumicell — to detect residual tumor tissue in breast cancer patients undergoing surgery is in the planning ... Read more

September 7, 2017

Even Small Breast Tumors Can be Aggressive, and Patients Can Benefit from Chemotherapy, Study Shows

News

While many doctors consider small tumors less harmful, new data from the international MINDACT breast cancer study suggests otherwise. In the study, nearly one in four early-stage breast cancer patients with ... Read more

September 5, 2017September 5, 2017

FDA Approves Faslodex As First-Line Therapy for HR+, HER2– Advanced Breast Cancer

News

The U.S. Food and Drug Administration has approved Faslodex (fulvestrant) as a first-line treatment for patients with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, therapy ... Read more

July 18, 2017

Nerlynx Approved by FDA for HER2-positive Breast Cancer Patients to Reduce Risk of Recurrence

News

The U.S. Food and Drug Administration (FDA) approved Puma Biotechnology‘s Nerlynx (neratinib) as an extended adjuvant treatment of early-stage, HER2-positive breast cancer. This means that Nerlynx is the first extended adjuvant therapy for ... Read more

June 9, 2017September 20, 2017

Keytruda Helped Patients with Metastatic Triple-Negative Breast Cancer, Studies Find

News

Keytruda (pembrolizumab) was effective in treating triple-negative breast cancer regardless of whether women had received previous treatment, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual ... Read more

June 8, 2017July 11, 2019

Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis

News

Combining Puma Biotechnology’s candidate therapy PB272, also known as neratinib, with the chemotherapy drug Xeloda (capecitabine) appears to have therapeutic potential for patients with advanced HER2-positive breast cancer and brain metastasis, who were not previously treated with ... Read more

June 7, 2017

Pregnancy Does Not Increase Chances of Breast Cancer Recurrence, Study Finds

News

A retrospective study investigated the safety of pregnancy after breast cancer in young women diagnosed with non-metastatic breast cancer. Data analysis shows that women who become pregnant after breast cancer diagnosis ... Read more

June 6, 2017June 6, 2017

Lynparza Shrinks Breast Cancer Tumors at Double the Rate of Chemo, Study Shows

News

The ovarian cancer therapy Lynparza (olaparib) shrank the tumors of 60 percent of breast cancer patients treated with it, double the figure for standard chemotherapy, according to a study. Lynparza, a PARP ... Read more

June 5, 2017June 7, 2017

Kisqali, Femara Combo Shows Promise in HR+/HER2- Advanced Breast Cancer Patients

News

The latest results from the Phase 3 MONALEESA-2 study showed that adding Novartis’ Kisqali (ribociclib) to ‎Femara (letrozole) for the treatment of breast cancer in certain postmenopausal women improves the time ... Read more

June 2, 2017

Susan G. Komen Launches New Toll-free Clinical Trial Information Helpline for Breast Cancer Patients

News

Susan G. Komen, an organization that fights breast cancer by funding research, screening, education, treatment, and psychosocial support programs, has launched a new toll-free Breast Cancer Clinical Trial Information Helpline (1-877-465-6636). ... Read more